Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar
Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.
Imagine spending years developing a potentially first-of-its-kind therapy, one that could treat a disease with zero approved treatments, and then selling the commercialization rights for less than what some Bay Area homes cost.
That's roughly what Moderna just did.
The Deal That Made Analysts Wince
Moderna licensed out mRNA-3927, a late-stage mRNA therapy for propionic acidemia, to Italian rare disease specialist Recordati. The price tag: A $50 million upfront payment plus up to $110 million in development and regulatory milestones. Moderna also gets undisclosed commercial milestones and tiered royalties if the drug reaches market.
On paper, the total deal could be worth around $160 million plus royalties. But Leerink Partners analyst Mani Foroohar didn't mince words. He called it a "garage sale" with "modest" terms, and honestly, it's hard to disagree.
For context, this is a therapy that's already in a registrational study, the final stage before seeking approval. The trial is fully enrolled, with a readout expected by the end of 2026. That's not some preclinical science project scribbled on a napkin; that's a drug knocking on the FDA's door.
What mRNA-3927 Actually Does
Propionic acidemia is one of those diseases most people have never heard of, and that's part of the problem. It's a rare genetic metabolic disorder where the body can't properly break down certain proteins and fats. Toxic byproducts build up, leading to what doctors call "metabolic decompensation events," essentially metabolic crises that can be life-threatening.
Think of it like a factory with a broken waste disposal system. The machinery keeps running, but the toxic junk piles up until something gives.
Right now, there are no approved disease-modifying therapies for propionic acidemia. Patients manage with strict diets and emergency interventions, but nothing addresses the root cause. mRNA-3927 is designed to fix that by delivering mRNA that encodes the two protein subunits the body is missing, essentially giving the factory a working waste disposal system.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Interim data from the Phase 1/2 trial showed a 70% reduction in the risk of metabolic crises among patients who'd experienced them in the prior year. No dose-limiting toxicities were reported, though adverse events were common, showing up in about 94% of participants, mostly transient.
That efficacy signal, for a disease with zero approved treatments, is the kind of result that usually gets investors excited. Instead, Moderna is handing the commercial keys to someone else for what amounts to a modest down payment.
Why Would Moderna Do This?
The short answer: Moderna is in full retreat-and-refocus mode.
The company has been aggressively restructuring. It cut 10% of its workforce and slashed $1.1 billion from its R&D budget. Four programs got discontinued outright, including congenital cytomegalovirus and herpes simplex virus candidates. The company is consolidating around two big bets: respiratory vaccines and oncology.
Respiratory vaccines, led by Spikevax and newer products like mRESVIA, form what Moderna calls the "foundation" for funding everything else. The goal is cash breakeven by 2028 and a 10% revenue bump in 2026. Oncology is the company's chosen growth engine, with nine clinical readouts expected over the coming years, including Phase II melanoma and lung cancer data.
Rare disease, meanwhile, looks increasingly like the middle child who didn't get invited to the family photo. Moderna isn't abandoning it entirely; the company still has mRNA-3705 for methylmalonic acidemia heading toward a registrational study in 2026, and mRNA-3745 for glycogen storage disease in Phase 1. But the Recordati deal sends a clear signal about where rare disease sits in the priority stack.
It's worth noting that under this deal structure, Moderna keeps control of clinical development and manufacturing while Recordati handles global commercialization. So Moderna still does the heavy lifting: it just gave away the upside of selling the drug.
The "Garage Sale" Math
Let's put $50 million upfront in perspective.
Solaxa recently licensed SLX-100, a clinical-stage small molecule for a rare neurological condition, to Alvogen for up to $95 million in milestones. That drug is earlier in development than mRNA-3927 and uses a far less novel mechanism. A small molecule deal for a mid-stage asset got 60% of the total value that Moderna's late-stage, potentially first-in-class mRNA therapy pulled.
Historically, late-stage rare disease assets with strong efficacy signals and no competition have commanded deal values well north of $160 million. Moderna's deal looks like what you'd expect for a Phase 1 asset with uncertain data, not a registrational-stage therapy showing 70% risk reduction.
The low price suggests something uncomfortable: nobody was fighting to get this asset. When you're holding a rare disease mRNA therapy and the market yawns, that tells you the buy side had real concerns, whether about the 94% adverse event rate, the complexity of mRNA manufacturing and distribution, or the commercial ceiling for an ultra-rare disease.
What This Means for Moderna's Story
Moderna's stock had actually been on a tear before this deal dropped, climbing nearly 50% in the month prior. The Recordati announcement barely dented it, shares dipped only slightly in early trading. Wall Street, it seems, has already mentally written off the rare disease portfolio.
And that might be the most telling detail of all. When a company sells a late-stage, first-in-class asset at bargain bin prices and the stock doesn't flinch, it means investors were never pricing it in to begin with. Moderna's valuation is riding on vaccines and cancer drugs. Rare disease was always the side project.
For Recordati, this could be a steal. The Italian company specializes in rare diseases and has the commercial infrastructure to actually sell a drug like this in small, specialized markets around the world. If mRNA-3927's pivotal data holds up later this year, Recordati could end up with the first approved therapy for propionic acidemia, bought at a price that would barely cover a mid-tier biotech Series B round.
The Bigger Picture
Moderna's garage sale is a microcosm of a broader tension in biotech. Companies love to talk about rare disease (it's noble, it's scientifically interesting, and the FDA bends over backward to help with orphan drug incentives). But when cash gets tight and investors want results, rare disease programs are often the first thing on the chopping block.
The patients with propionic acidemia don't care about Moderna's oncology pivot or its path to cash breakeven. They care about whether mRNA-3927 works and when they can get it. With Recordati now at the commercial helm, the drug's development continues. The pivotal data is coming by year-end.
The therapy's future is intact. Moderna just won't be the one profiting from it, at least not nearly as much as it could have.
Deals & M&A
5 min read
Lilly Just Paid $85M to Teach Your Immune System Some Manners
Eli Lilly just dropped $85 million upfront, with $1.84 billion more on the table, to partner with Repertoire Immune Medicines on a radical idea: retraining the immune system instead of suppressing it. If it works, autoimmune patients might finally escape lifelong drug regimens.
